cpx-351 for high-risk aml
Published 4 years ago • 95 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
2:11
cpx-351 plus venetoclax in patients with newly-diagnosed high-risk aml
-
1:12
cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
-
3:48
cpx-351 for secondary aml: pharmacokinetics, administration & impact on treatment
-
3:07
improved understanding of cpx-351 in aml: impact of hct & final eap results
-
2:16
cpx-351 in poor risk aml patients
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
5:09
what do you see as the future of aml treatments? #aml
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
2:29
cpx-351 vs 7 3 in older high-risk aml patients
-
5:03
combining venetoclax with cpx-351 for aml
-
1:02
aml19: flag-ida vs cpx-351 in patients with aml with adverse risk cytogenetics
-
1:19
predicting the outcomes of patients with aml treated with cpx-351 based on eln risk stratification
-
1:55
long-term real-world experience of cpx-351 in patients with t-aml and mrc-aml
-
1:30
evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml
-
1:12
cpx-351 with venetoclax in r/r aml: results of a phase ib study
-
1:55
cardiotoxicity of cpx-351 vs 7 3 chemotherapy in patients with untreated high-risk aml
-
2:01
analyzing the cost-effectiveness of cpx-351 in patients with aml
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
3:03
cpx-351 vs. hma plus venetoclax in the treatment of patients with aml
-
1:47
choosing between cpx-351 and flag-ida in newly diagnosed and r/r aml
-
1:34
v-fast subgroup analysis: cpx-351 plus midostaurin for newly diagnosed flt3-mutated aml